(lp0
S'Market: The Alnylam Pharmaceuticals, Inc.  Director Philip A. Sharp ... Petro Global News 24 - Jan 28, 2017 Shares of Alnylam Pharmaceuticals, Inc.  opened at 38.09 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $80.11. The firm has a 50 day moving average price of $40.87 and a 200-day moving&nbsp;...'
p1
aS'Stocks: The Rhumbline Advisers Boosts Position in Alnylam Pharmaceuticals, Inc ... Petro Global News 24 - Jan 19, 2017 A number of other hedge funds have also bought and sold shares of ALNY. Nisa Investment Advisors LLC acquired a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $128,000. Meeder Asset Management Inc. acquired a new&nbsp;...'
p2
aS'Patisiran, Chronicle Of A Death Foretold Seeking Alpha - Apr 10, 2017 Alnylam Pharmaceuticals Inc.  is a biopharmaceutical company headquartered in Cambridge, MA, USA. Alnylam [Website] is one of the pioneers in discovering, developing, and commercializing novel therapeutics for genetically defined&nbsp;...AQR Capital Management LLC Invests $1.036 Million in Alnylam Pharmaceuticals ... - Sports Perspectives$27.63 Million in Sales Expected for Alnylam Pharmaceuticals, Inc.  This ... - Markets Daily'
p3
aS'Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It Motley Fool - Feb 9, 2017 The Medicines Company  presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with&nbsp;...Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ... - Business Wire Alnylam  Q3 Loss Narrower than Expected, Revenues Rise - Nasdaq'
p4
aS"Here's Why Alnylam Pharmaceuticals, Inc. Stock Bounced Up 10.1% Today Motley Fool - Feb 27, 2017 Shares of Alnylam Pharmaceuticals, Inc.  a clinical-stage biotech, notched a 10.1% gain to end Monday's session.How Do Analysts View Alnylam Pharmaceuticals in 2017? - Market Realist"
p5
aS'Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. Motley Fool - Feb 20, 2017 Late last year, Alnylam Pharmaceuticals, Inc.  took a big hit when the company scuttled an important development program because of safety concerns.'
p6
aS'Analyst Activity  BMO Capital Markets Initiates Coverage On Alnylam ... Market Exclusive - 21 hours ago The current consensus rating on Alnylam Pharmaceuticals  is Buy  with a consensus target price of $65.44 per share, a potential 31.27% upside.Alnylam Pharmaceuticals, Inc.  Short Interest Update - Midway MonitorCompany Stock Review for Alnylam Pharmaceuticals, Inc.  - Baldwin Journal'
p7
aS'Decision Time: Alnylam Pharmaceuticals Inc  Stock Technicals Hit ... CML News - 21 hours ago Decision Time: Alnylam Pharmaceuticals Inc  now sits in the perhaps the most difficult technical position -- the stock has no urgency in its direction and that has left it at an inflection point.'
p8
aS'Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma ... PR Newswire  - Apr 12, 2017 This Wednesday morning, Stock-Callers.com looks at the performance of these four Biotechnology stocks: Tesaro Inc. , Alnylam Pharmaceuticals Inc. , Corbus Pharmaceuticals Holdings Inc. , and Inovio&nbsp;...'
p9
aS"Analysts Take Aim At This Stock's Earnings Estimates: Alnylam Pharmaceuticals ... Aiken Advocate - 21 hours ago When a company reports earnings, the reports are intensely examined by investors and analysts alike. Earnings are important because they can give insight into the profitability of a company. Covering Street analysts are looking for Alnylam ..."
p10
a.